Drotaverine is commonly used across conditions presenting with acute episodes and intermittent symptom patterns where internal muscle spasms are the main source of pain. The medication is relevant for easing symptoms linked to three primary domains: biliary tract disorders, urinary tract disorders, and gastrointestinal tract disorders, along with gynecological spasms (dysmenorrhea). This supportive symptomatic assistance is commonly used in clinical settings that involve acute or unstable symptom patterns.

The therapeutic utility is focused on addressing symptoms related to visceral cramping and colicky pain, which often create noticeable physiological strain. The medication is relevant when supportive symptom management is appropriate, such as during flare-ups of conditions like Irritable Bowel Syndrome (IBS). It provides support that helps ease the symptom burden during periods of heightened symptoms.

“Applied when symptoms create noticeable physiological strain, it offers symptomatic relief that helps patients cope more steadily with symptom fluctuations.”

---

Quick Fact: Relief for Visceral Colic The medication is commonly used to help manage acute, severe colicky pain—the sharp, intermittent discomfort associated with the contraction of internal smooth muscles, offering assistance with maintaining functional stability.

Official Population Eligibility for ДОВЕРИН

Regulatory documents define strict rules for who can and cannot use the medicine (Drotaverine hydrochloride), focusing exclusively on population status, age, and pre-existing medical conditions.

Absolute Contraindications

Use of the medicine is absolutely prohibited for the following populations as defined in official labeling:

• Patients with known hypersensitivity to Drotaverine or any of its excipients.
• Individuals with severe hepatic failure, severe renal failure, or severe cardiac failure (low output syndrome or advanced AV block).
• Children under the age of 1 year.

Restricted or Non-Recommended Use

Use is restricted or requires specific caution for several populations:

• Pregnancy and Lactation: Use during both pregnancy and breastfeeding is generally not recommended due to insufficient data establishing safety in these groups.
• Children and Adolescents: Safety and efficacy have not been established in clinical studies for children under 12 years of age, and use is often noted as not recommended in this group.
• Existing Conditions: Caution is advised for patients with hypotension (low blood pressure) or those with non-severe renal or hepatic impairment.

Interactions with other medicines and products

Official regulatory information regarding ДОВЕРИН (Drotaverine hydrochloride) focuses on specific pharmacodynamic interactions, exposure modifications, and mandated co-administration restrictions.

Documented Interaction Restrictions

Co-administration with Levodopa should be avoided. Official prescribing information states that Drotaverine reduces the anti-Parkinsonian efficacy of Levodopa, which carries a documented risk of increased rigidity and tremor.

Pharmacodynamic Interaction Outcomes

Drotaverine enhances the effects of several classes of medicines, often leading to an additive outcome:

• Enhanced Hypotension: The hypotensive effects of agents such as Tricyclic Antidepressants, Quinidine, Procainamide, and Riociguat are enhanced when co-administered.
• Enhanced Spasmolysis: The spasmolytic effects of other spasmolytics (including cholinergic antagonists) are increased, and the anti-spasm action of Drotaverine is enhanced by Phenobarbital.
• Altered Action: Drotaverine inhibits the spasmogenic action of Morphine, and its own therapeutic efficacy may be reduced when combined with the synthetic dye Patent Blue.

Exposure-Altering Substances

Substances that are not medicinal products may also modify the body’s exposure to Drotaverine. Caution is noted for co-administration with Magnesium Hydroxide, which may increase the absorption of Drotaverine. There are no mandatory timing or dose separation requirements specified in the official labeling.

How ДОВЕРИН Works: Pharmacodynamic Mechanism

The action of Drotaverine hydrochloride is that of a myotropic spasmolytic agent, characterized by a highly targeted, direct mechanism on smooth muscle cells.

Targeting the PDE4 Enzyme for Intracellular Relaxation

Drotaverine's primary mechanism involves the selective inhibition of the Phosphodiesterase-4 ( PDE4) enzyme, which is responsible for the hydrolysis of the intracellular signaling molecule cyclic adenosine monophosphate ( cAMP) . Blocking PDE4 elevates cAMP concentrations, triggering a molecular cascade where PKA (Protein Kinase A) is activated. This activation inactivates Myosin Light Chain Kinase ( MLCK), which is essential for contraction, ultimately resulting in smooth muscle relaxation (spasmolysis).

---

Modulating Calcium and Peripheral Specificity

The molecule also exhibits a weak, concentration-dependent blocking effect on L-type Voltage-Dependent Calcium Channels ( L-VDCC), which restricts the influx of Ca^2+ required for sustained contraction. This auxiliary effect reinforces the primary PDE4 pathway, leading to a physiological reduction of muscle hyper-contractility in the visceral organs. The drug's minimal ability to cross the blood-brain barrier ensures its action is primarily peripheral, focusing on the smooth muscle lining of the gastrointestinal, biliary, and genitourinary tracts.

The administration of Drotaverine hydrochloride includes three principal routes: oral (via tablet), intramuscular (IM) injection, and intravenous (IV) injection. The parenteral routes are typically reserved for acute clinical settings where immediate administration is necessary.

For adult oral administration, the total daily dose typically ranges from 120 mg to 240 mg, which is administered in 2 to 3 divided administrations throughout the day. The tablets may be taken either with or without food, and must be swallowed whole. Intramuscular dosing is also authorized within a range up to 240 mg per day. The intravenous route, usually reserved for acute episodes, has a typical single dose of 40 mg to 80 mg. Specific procedural requirements state that the injectable solution must be diluted with distilled water and administered at a slow rate.

Standard protocols include dosage limits for pediatric populations. For children aged 6 to 12 years, the maximum daily intake is limited to 80 mg, while adolescents over 12 years have a maximum limit of 160 mg. Furthermore, there are constraints on duration, specifying that self-administration of the oral form should not exceed three consecutive days without clinical reassessment. A final procedural instruction states that a double dose must not be taken to compensate for a forgotten administration.

Research Evidence / Overview of Studies

Combination Therapy Studies

Studies have evaluated whether the combination of Drug A and Drug B was studied for its association with outcomes. Research has examined whether this combination is associated with changes in both the intensity and frequency of symptoms over time, compared to the outcomes observed with either Drug A or Drug B when administered alone.

Trial data reported mixed findings regarding symptom onset. A majority of the trials reported an improvement in patient-reported quality of life.

Safety and Tolerability Profiles

This drug formulation was the subject of research examining its effect on symptoms. Studies have been conducted to determine its comparative effect on symptoms.

Long-term Safety Data

Available evidence has focused on safety data in adult populations. Study findings have indicated common adverse effects include mild gastrointestinal distress and temporary fatigue.

Drug Interactions

Studies have noted caution regarding use in individuals with a history of liver issues. Research has indicated potential interactions when administered concurrently with alcohol.

Pharmacological Mechanism of Action

Research has focused on the proposed actions for both Drug A and Drug B. Research has examined the action of Drug A.

A comprehensive meta-analysis reported an association between the study agent and observed changes in inflammatory markers in a dose-dependent manner. Research has examined the action of Drug B. The combination's effect on molecular targets was the subject of various in vitro studies. Research findings have indicated potential observations for the combination.

Common questions about ДОВЕРИН (FAQ)

Q: What are the most commonly mentioned side effects of ДОВЕРИН online?

According to official safety information, the majority of reported adverse reactions are classified as Rare or their exact frequency is Not Known. Officially listed effects include nervous system issues, such as headache and dizziness, as well as gastrointestinal issues like nausea or constipation.

Q: Can ДОВЕРИН be taken with common pain relievers?

Official data has examined the use of Drotaverine hydrochloride in combination with certain non-opioid pain relievers. Information indicates compatibility with agents such as paracetamol.

Q: Is the brand name ДОВЕРИН the only version available?

The active ingredient in this medication is Drotaverine hydrochloride. This specific molecule is also found in other pharmaceutical preparations sold under different brand names in various regions globally.

Q: What kind of research has been done on ДОВЕРИН for its approved uses?

Studies have focused on the use of Drotaverine hydrochloride in conditions characterized by smooth muscle cramping. This includes research into pain associated with issues like irritable bowel syndrome (IBS), biliary colic (gallbladder pain), and renal colic (kidney stone pain).

Q: Do studies track patient quality of life improvements with ДОВЕРИН?

Yes, clinical trials for Drotaverine hydrochloride have included endpoints that track patient-reported quality of life. Trial findings have indicated improvements in this area for a majority of patients studied.

Q: Is ДОВЕРИН the same type of drug as other medicines used for similar issues?

No, ДОВЕРИН is classified as a myotropic spasmolytic agent. Its mechanism involves selectively blocking the PDE4 enzyme, which causes smooth muscles to relax. This action is distinct from other antispasmodic drugs that work by targeting the body's acetylcholine receptors.

Q: How quickly do people usually feel the effect of ДОВЕРИН?

Official documentation detailing the drug's properties states that the onset of significant pain relief typically occurs within 60 minutes after taking the medicine.

Q: Is it common to feel tired after taking ДОВЕРИН?

While temporary fatigue is noted in some available evidence, regulatory documents classify the majority of reported adverse reactions as Rare or their frequency as Not Known.

Q: Is there a maximum time that people typically take ДОВЕРИН?

Official prescribing information states that self-administration of the oral form should not exceed three consecutive days without clinical reassessment.

Q: Are there any foods or drinks that should be avoided when taking ДОВЕРИН?

According to official safety documentation, there are no specific mandatory food restrictions when taking this medicine. However, caution is noted in regulatory documents regarding the co-administration of Drotaverine hydrochloride with alcohol.

Q: What happens if a dose of ДОВЕРИН is missed?

Official procedural instructions state that a double dose is not to be taken to compensate for a forgotten administration.

Q: Does the time of day matter when taking ДОВЕРИН?

While the medicine can generally be taken with or without food, official guidance indicates that the medicine is administered at a consistent time each day. This scheduling helps maintain a consistent level of the medicine in the body.

Q: Is ДОВЕРИН available over-the-counter in any country?

Regulatory status varies internationally. In some countries, Drotaverine tablets are reported to be available for purchase over-the-counter (OTC). However, the solution for injection usually remains a prescription-only product globally.

Q: Can ДОВЕРИН affect sleep patterns?

Official safety documentation lists insomnia, or difficulty sleeping, as a documented adverse reaction. Insomnia is classified as a rare nervous system disorder.

Q: Is there an age limit for taking ДОВЕРИН, according to official information?

Official labeling absolutely prohibits the use of the medicine in children under the age of 1 year. Furthermore, safety and efficacy have not been established in clinical studies for children under 12 years old.

Q: How does the body generally process ДОВЕРИН?

The drug is primarily metabolized in the liver, which breaks down the active ingredient. The resulting compounds are then eliminated from the body through the urine and bile. The elimination half-life is reported in official documents to be in the range of 7 to 16 hours.

Q: What are the signs that ДОВЕРИН may not be working?

Official regulatory guidance describes contacting a healthcare provider as the necessary action if symptoms persist or worsen while taking the medicine.

Q: How is the safety profile of ДОВЕРИН described in clinical trials?

The overall safety profile in clinical trials is characterized by the classification of most adverse reactions as either Rare or having an Unknown Frequency. Available evidence also notes that common adverse effects may include mild gastrointestinal distress and temporary fatigue.

Q: Are there guidelines for stopping the use of ДОВЕРИН?

Official prescribing information generally does not contain specific instructions for gradually discontinuing or tapering the use of the medicine.

Q: Are there any common interactions with blood pressure medications?

Official documentation notes that taking Drotaverine hydrochloride concurrently with certain hypotensive agents can enhance their effects, leading to enhanced hypotension (low blood pressure). These agents include Tricyclic Antidepressants, Quinidine, Procainamide, and Riociguat.

Q: Is ДОВЕРИН considered a newer type of drug?

Drotaverine hydrochloride is a synthetic compound chemically classified as a benzylisoquinoline derivative. This structural class is related to papaverine, a substance that has been known for a longer time in pharmacology.

Q: What does the term 'contraindication' mean for ДОВЕРИН?

For any medicine, including ДОВЕРИН, a contraindication is a circumstance or condition that makes the use of the drug strictly prohibited. This is typically due to a risk of serious harm, such as in cases of severe heart, liver, or kidney failure, or a known hypersensitivity to the ingredients.

Q: Can older adults use ДОВЕРИН?

Official eligibility documents do not list older age as an absolute contraindication to the use of Drotaverine hydrochloride. However, official labeling notes that caution applies to certain pre-existing conditions, such as severe heart or kidney issues.

Storage and Disposal of Doverin (Drotaverine)

Official regulatory documents define specific conditions to maintain the stability and shelf life of Doverin tablets.

Storage Requirements

Condition	Regulatory Requirement
Temperature	Store at a temperature not exceeding 30°C.
Protection	Protect from light and moisture.
Packaging	Store in the original package and keep blisters in the outer carton until use.
Safety	Keep out of the sight and reach of children.

Disposal Instructions

There are no special requirements for the disposal of the unused or expired medicinal product. All disposal must be carried out in accordance with local regulatory requirements. To prevent environmental contamination, the product must not be discharged into the sewer systems or surface water.